Alnylam Pharmaceuticals, Inc. (ALNY) Position Cut by Balyasny Asset Management LLC
Balyasny Asset Management LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 95.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,861 shares of the biopharmaceutical company’s stock after selling 194,606 shares during the period. Balyasny Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $707,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in ALNY. QS Investors LLC boosted its holdings in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 900 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Alnylam Pharmaceuticals during the first quarter worth $215,000. CIBC Asset Management Inc purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $221,000. Neuberger Berman Group LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $229,000. Finally, Capstone Asset Management Co. purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $232,000. 94.25% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 118.70 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.38 and a 52-week high of $126.16. The firm’s market capitalization is $10.89 billion. The company’s 50-day moving average is $100.82 and its 200 day moving average is $77.74.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company’s revenue was up 82.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.05) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.20) earnings per share for the current fiscal year.
ALNY has been the topic of a number of recent analyst reports. Piper Jaffray Companies reissued an “overweight” rating and set a $126.00 price target (up from $116.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 21st. Jefferies Group LLC reissued a “buy” rating and set a $102.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 22nd. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. Credit Suisse Group increased their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a report on Tuesday, June 27th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 26th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $100.80.
ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Position Cut by Balyasny Asset Management LLC” was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/10/18/alnylam-pharmaceuticals-inc-alny-position-cut-by-balyasny-asset-management-llc.html.
In other news, President Barry E. Greene sold 85,316 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.